MULTIPURPOSE ARTHRITIS & MUSCULOSKELETAL DISEASE CENTER

这是一种多用途关节炎的续订申请， 肌肉骨骼疾病中心。该中心带来了 风湿病的医疗和卫生服务研究活动 圣地亚哥地区四个机构的疾病：圣迭戈大学 加州，圣地亚哥，斯克里普斯研究所，索尔克 生物研究所和拉霍亚过敏研究所 和免疫学(L.J.I.A.I.)。生物医学研究部门 MAMDC要求为五个创新发展项目提供资金 和与基本病因相关的可行性项目 风湿病。P.I.、M.Croft(L.J.I.A.I.)将决定 CD_4淋巴细胞亚群在发育和发育中的重要性 类风湿关节炎动物模型的研究进展。P.I.、L. 冯，(斯克里普斯)将剖析化学吸引蛋白的作用 IL-8和MCP-1在实验性关节炎中的作用私家侦探D·格林 (L.J.I.A.I.)将检验一种新的假说，即 P53可导致类风湿滑膜细胞的异常凋亡， C.Rivier，(Salk)将分析 下丘脑激素促肾上腺皮质激素释放因子，以及 促炎细胞因子肿瘤坏死因子-a在实验性中的作用 关节炎。P.I.，M.P.，Corr(UCSD)将使用基因疗法 调节抗原特异性免疫反应，而不诱导 全身免疫抑制。教育学、流行病学和 医疗服务研究(EEHSR)部分包括两个部分 侧重于健康结果评估的提案，以及他们的 风湿病患者的经济后果。 EEHSR项目1 P.I.，T，Ganiats，(UCSD)将确定 患者以类似的方式对关节炎的健康结果进行折扣 财政资源，并将调查患者是否 患有风湿病的人更喜欢短期利益而不是长期利益 后果。下一个项目，P.I.，R.Kaplan，(UCSD)将使用 一种新的自我管理幸福感(QWB)量表 测量慢性肌肉骨骼疾病患者的健康结局 疾病。MAMDC的生物医学成分和EEHSR成分 将由三个核心支持。行政当局(H.G.Bluestein， 董事)将提供总体指导和评估 MAMDC通过一个由外部协助的执行委员会 咨询委员会：它将提供日常管理和 所有MAMDC项目的临床专业知识。分子生物学 CORE(P.P.陈主任)将促进及时利用 内科医生和科学家的分子生物学技术 中心，并将领导一个共享的仪器设施。这个 生物统计核心(C.Berry，董事)将为 中心的研究人员，并将建立一个新的遗传流行病学 专注于关节炎和肌肉骨骼的全球网站 精神错乱。

This is a renewal application for a Multipurpose Arthritis and Musculoskeletal Disease Center (MAMDC). The Center brings together medical and health services research activities in rheumatic diseases at four institutions in the San Diego area: the University of California, San Diego, The Scripps Research Institute, the Salk Institute for Biological Studies, and the LaJolla Institutes for Allergy and Immunology (L.J.I.A.I). The Biomedical Research Component of the MAMDC requests funding for five innovative developmental and feasibility projects related to the fundamental etiopathogenesis of rheumatic disease. P.I., M. Croft, (L.J.I.A.I.) Will determine the importance of CD4 lymphocyte subsets in the development and progression of an animal model of rheumatoid arthritis. P.I., L. Feng, (Scripps) will dissect the role of the chemoattractant proteins IL-8 and MCP-1 in experimental arthritis. P.I., D. Green, (L.J.I.A.I.) will test the novel hypothesis that somatic mutations of p53 can lead to aberrant apoptosis in the rheumatoid synovium P.I., C. Rivier, (Salk) will analyze the relationship between the hypothalamic hormone corticotrophin releasing factor, and the proinflammatory cytokine tumor necrosis factor a, in experimental arthritis. P.I., M.P., Corr (UCSD) will use gene therapy to modulate antigen-specific immune responses, without inducing general immunosuppression. The Education, Epidemiology, and Health Services Research (EEHSR) Component encompasses two proposals that focus on health outcome assessments, and their economic consequences, in patients with rheumatic diseases. EEHSR Project 1 P.I., T, Ganiats, (UCSD) will determine if patients discount health outcomes in arthritis in a manner analogous to financial resources, and will investigate whether or not patients with rheumatic diseases prefer near-term benefits to far-term consequences. The next Project, P.I., R. Kaplan, (UCSD) will use a new self-administered quality of well-being (QWB) scale to measure health outcome in patients with chronic musculoskeletal diseases. The Biomedical and EEHSR components of the MAMDC will be supported by three cores. Administration (H.G. Bluestein, Director) will provide overall direction and evaluation of the MAMDC through an Executive Committee assisted by an Outside Advisory Committee: and it will provide day-to-day management and clinical expertise for all MAMDC projects. The Molecular Biology Core (P.P. Chen, Director) will facilitate the timely utilization of molecular biology techniques by physicians and scientists in the Center, and will direct a shared instrumentation facility. The Biostatistics Core (C.Berry, Director) will provide consultation to Center investigators, and will set up a new genetic epidemiology world-wide web site with a focus on arthritis and musculoskeletal disorders.